G Protein News and Research

RSS

Ranaz Corporation to raise funds through private placement

Ranaz Corporation ("Ranaz") (TSXV: RNZ), a company specialized in the manufacturing and marketing of protein and dietary supplements, announces that it intends to raise $675,000 through a non-brokered private placement of units.

29 Aug 2009

Ranaz reports second quarter 2009 financial results

Ranaz Corporation ("Ranaz"), a company specialized in the manufacturing and marketing of protein and dietary supplements, reported its results today for the second quarter ended June 30, 2009.

29 Aug 2009

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

A common antibiotic can function as an "off switch" for a gene therapy being developed for Parkinson's disease, according to University of Florida researchers writing online in advance of September's Molecular Therapy.

29 Aug 2009

Researchers discover that some wild plants possess a high nutritional value

A group of researchers from the Fat Institute (CSIC) and the University of Seville have confirmed that some wild plants have a high nutritional value. The scientists have found that several species of lupins from the mountains of Andalusia have a protein content similar to that of other cultivated legumes, as they publish in the online version of the Food Chemistry magazine.

28 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone. New findings by researchers at Fred Hutchinson Cancer Research Center, published online Aug. 27 in Science, suggest that in nematode worms, at least, this does not hold true.

28 Aug 2009

Enzymes could be targeted to kill dangerous pathogens

Researchers at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens.

28 Aug 2009

Carbon nanotubes may help regrow nerve tissue according to a research study

Carbon nanotubes hold many exciting possibilities, some of them in the realm of the human nervous system. Recent research has shown that carbon nanotubes may help regrow nerve tissue or ferry drugs used to repair damaged neurons associated with disorders such as epilepsy, Parkinson's disease and perhaps even paralysis.

28 Aug 2009

TRAF6 protein can activate a cell signalling molecule associated with cancer

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

28 Aug 2009

FDA provides marketing clearance for the spinal implant developed by Sanford Health

Sanford Health, a comprehensive health care provider in the Upper Midwest, announced today a spinal implant developed by Sanford Clinic Neurosurgeon, Wilson Asfora, MD, Sanford Clinic Neurosurgery & Spine, has received United States Food and Drug Administration (FDA) 510(k) market clearance as a lumbar intervertebral body fusion device.

28 Aug 2009

USPTO awards two new patents to Nerites

Nerites Corporation announced Thursday that the United States Patent and Trademark Office (USPTO) issued two new patents covering the company’s technology. These “composition of matter” patents provide underlying intellectual property protection for surgical adhesives, films, and coatings. Nerites’ scientists create synthetic mimetics of the protein components used by marine mussels to stick to rocks under water.

28 Aug 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Cell cycle checkpoints act like molecular tripwires for damaged cells, forcing them to pause and take stock. Leave the tripwire in place for too long, though, and cancer cells will press on regardless, making them resistant to the lethal effects of certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.

28 Aug 2009

Fatostatin lowers the activity of genes associated with cholesterol synthesis

A small molecule earlier found to have both anti-fat and anti-cancer abilities works as a literal turnoff for fat-making genes, according to a new report in the August 28th issue of the journal Chemistry and Biology, a Cell Press journal.

27 Aug 2009

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics is pleased to announce that one of the patients, who was treated with the Company’s EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company’s phase I/II anemia trial in Israel.

27 Aug 2009

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Haber, Inc. (“Haber”), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called “EMP Diagnostics Inc.” (“EDI”). The business of the new company will focus on the application of Haber’s Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.

27 Aug 2009

New genetic mechanism to control body's fat-building process identified

At a time of alarming increases in obesity and associated diseases -- and fiery debates about the cost of health care -- a UCF research team has identified a new genetic mechanism that controls the body's fat-building process.

27 Aug 2009

Amateur boxing leads to increased levels of brain damage markers in spinal fluid

A blood test can now be used to detect brain damage in amateur boxers. Deterioration of nerve cells seems to occur even after a two-month break from boxing. This is shown in a new study from the Sahlgrenska Academy, University of Gothenburg, Sweden.

27 Aug 2009

Researchers devise a live cell morphological profiling approach using the xCELLigence RTCA System

The extent to which protein targets are modulated by drugs or small molecule compounds depends on a number of factors, including the expression levels of the target, the effective concentration of the compound, and the time needed for the compound to perturb the target. To address these restrictions, researchers Abassi et al. (1) have devised a live cell morphological profiling approach for dynamic monitoring of the effect of small molecule compounds that was based on impedance measurement of cells with the xCELLigence RTCA System of Roche Applied Science.

27 Aug 2009

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.

27 Aug 2009

G Protein News and Research

Ranaz Corporation to raise funds through private placement

Ranaz reports second quarter 2009 financial results

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

Researchers discover that some wild plants possess a high nutritional value

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Enzymes could be targeted to kill dangerous pathogens

Carbon nanotubes may help regrow nerve tissue according to a research study

TRAF6 protein can activate a cell signalling molecule associated with cancer

FDA provides marketing clearance for the spinal implant developed by Sanford Health

USPTO awards two new patents to Nerites

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Fatostatin lowers the activity of genes associated with cholesterol synthesis

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

New genetic mechanism to control body's fat-building process identified

Amateur boxing leads to increased levels of brain damage markers in spinal fluid

Researchers devise a live cell morphological profiling approach using the xCELLigence RTCA System

Prevention and eradication of FVIII antibodies could improve hemophilia treatment

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News